EVALUATION OF NALMEFENE, AN ENDORPHIN ANTAGONIST, IN THE CONTROL OF APPETITE

这项研究旨在评估纳美芬的疗效--三分之一 代纳洛酮控制食欲。 最初的主题是 Prader-Willi综合征患者 药物剂量逐步增加， 一个三个星期的时间，每天40毫克。 然后对患者进行随访， 两个月的门诊，接受纳美芬两周， 与安慰剂交替使用两周。 在临床的最后一周 中心进行了仔细的评价。 药物治疗没有效果， 在食物摄入中发现。

The study was designed to assess the efficacy of nalmefene--a third generation naloxone in the control of appetite. The initial subjects were Prader-Willi Syndrome patients. The medication was increased stepwise over a three week period to 40 mg per day. The patients were then followed for two months in the outpatient department, receiving nalmefene for two weeks, alternating with placebo for two weeks. A final week in the Clinical Center was used for careful evaluation. No effect of the medication was found on food intake.